



# Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis

Ian R Reid, Mark J Bolland, Andrew Grey

## Summary

Lancet 2014; 383: 146–55

Published Online

October 11, 2013

[http://dx.doi.org/10.1016/S0140-6736\(13\)61647-5](http://dx.doi.org/10.1016/S0140-6736(13)61647-5)

See [Comment](#) page 108

Department of Medicine,  
Faculty of Medical and Health  
Sciences, University of  
Auckland, Auckland, New  
Zealand (Prof I R Reid MD,  
M J Bolland PhD, A Grey MD);  
and Department of  
Endocrinology, Auckland  
District Health Board,  
Auckland, New Zealand  
(I R Reid, A Grey)

Correspondence to:  
Prof Ian R Reid, Faculty of  
Medical and Health Sciences,  
University of Auckland,  
Private Bag 92019, Auckland,  
New Zealand  
[i.reid@auckland.ac.nz](mailto:i.reid@auckland.ac.nz)

**Background** Findings from recent meta-analyses of vitamin D supplementation without co-administration of calcium have not shown fracture prevention, possibly because of insufficient power or inappropriate doses, or because the intervention was not targeted to deficient populations. Despite these data, almost half of older adults (older than 50 years) continue to use these supplements. Bone mineral density can be used to detect biologically significant effects in much smaller cohorts. We investigated whether vitamin D supplementation affects bone mineral density.

**Methods** We searched Web of Science, Embase, and the Cochrane Database, from inception to July 8, 2012, for trials assessing the effects of vitamin D (D3 or D2, but not vitamin D metabolites) on bone mineral density. We included all randomised trials comparing interventions that differed only in vitamin D content, and which included adults (average age >20 years) without other metabolic bone diseases. We pooled data with a random effects meta-analysis with weighted mean differences and 95% CIs reported. To assess heterogeneity in results of individual studies, we used Cochran's *Q* statistic and the *I*<sup>2</sup> statistic. The primary endpoint was the percentage change in bone mineral density from baseline.

**Findings** Of 3930 citations identified by the search strategy, 23 studies (mean duration 23.5 months, comprising 4082 participants, 92% women, average age 59 years) met the inclusion criteria. 19 studies had mainly white populations. Mean baseline serum 25-hydroxyvitamin D concentration was less than 50 nmol/L in eight studies (n=1791). In ten studies (n=2294), individuals were given vitamin D doses less than 800 IU per day. Bone mineral density was measured at one to five sites (lumbar spine, femoral neck, total hip, trochanter, total body, or forearm) in each study, so 70 tests of statistical significance were done across the studies. There were six findings of significant benefit, two of significant detriment, and the rest were non-significant. Only one study showed benefit at more than one site. Results of our meta-analysis showed a small benefit at the femoral neck (weighted mean difference 0.8%, 95% CI 0.2–1.4) with heterogeneity among trials (*I*<sup>2</sup>=67%, *p*<0.00027). No effect at any other site was reported, including the total hip. We recorded a bias toward positive results at the femoral neck and total hip.

**Interpretation** Continuing widespread use of vitamin D for osteoporosis prevention in community-dwelling adults without specific risk factors for vitamin D deficiency seems to be inappropriate.

**Funding** Health Research Council of New Zealand.

## Introduction

Vitamin D, like calcium, has long been regarded as a fundamental part of the prevention and treatment of osteoporosis. Low vitamin D concentrations result in secondary hyperparathyroidism and accelerated bone loss, although the development of secondary hyperparathyroidism varies, even in patients with severe vitamin D deficiency.<sup>1,2</sup> Findings from observational studies show inconsistent associations between bone mineral density and vitamin D status,<sup>3,4</sup> and debate continues regarding optimum concentrations of 25-hydroxyvitamin D for the best possible skeletal health.<sup>5,6</sup> However, results from meta-analyses of trials of vitamin D alone (ie, not with calcium) failed to show an association between supplementation and fracture prevention.<sup>7,8</sup> This finding could be attributable to aspects of the study design (eg, study power, the population recruited, or the vitamin D dose used). Alternatively, vitamin D might not have a protective effect on bone, as has been postulated.<sup>7</sup> Therefore,

surrogate endpoints such as bone mineral density, which can be used to detect biologically significant effects in small cohorts, should be examined closer.

Furthermore, some studies might have used inadequate doses of vitamin D or a baseline vitamin D status of the populations studied that was not low enough for the intervention to produce a significant effect. Thus, the study of the effect of vitamin D supplementation on bone density in terms of the dose given and baseline vitamin D status are important questions that can be addressed in the many studies assessing bone mineral density. Concerns about the cardiovascular safety of calcium plus vitamin D supplements<sup>9</sup> warrant the investigation of vitamin D as a monotherapy.

We aimed to address these questions by systematically reviewing all randomised, controlled trials of cholecalciferol or ergocalciferol that have included bone mineral density data, irrespective of whether this was the primary endpoint of the study, in populations without other disorders likely to affect bone and

calcium metabolism. Despite the negative findings from fracture studies, almost half of adults in the USA use vitamin D supplements.<sup>10</sup> Therefore, to ensure appropriate targeting of this common intervention, investigators need to establish in which groups the vitamin improves bone health.

## Methods

### Search strategy and selection criteria

We did a systematic review and meta-analysis in accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and meta-Analyses) guidelines, and used a predetermined protocol. To qualify for inclusion,

	Trial duration (months)	N	Mean age (range; years)	Country	Sex (% female)	Mean 25OHD (SD or range; nmol/L)		Dietary calcium (mg/day)	Weight (kg)	Intervention	Co-interventions*	Comorbidities
						Baseline	On vitamin D					
Christiansen, 1980 <sup>18</sup>	24	149	50 (inclusion criteria 45-54)	Denmark	100	..	..	..	..	Vitamin D3 2000 IU/day vs placebo	Calcium 500 mg/day	..
Dawson-Hughes,† 1991 <sup>19</sup>	12	276	62	USA (white)	100	71‡	95§	390	68	Vitamin D3 400 IU/day vs placebo	Calcium 380 mg/day	..
Dawson-Hughes,† 1995 <sup>20</sup>	24	261	64	USA (white)	100	66‡ ± 25	100§	450	68	Vitamin D3 100 IU/day vs 700 IU/day	Calcium 500 mg/day	..
Ooms,† 1995 <sup>21</sup>	24	348	80 (inclusion criteria >70)	Holland	100	26¶ (19-37)	62§	About 1120¶	71	Vitamin D3 400 IU/day vs placebo	..	..
Tuppurainen,** 1998 <sup>22</sup>	48	45	55 (inclusion criteria 50-59)	Finland	100	..	..	730	61	Vitamin D3 300 IU/day for 9 of 12 months per year vs control	Hormone treatment	..
Komulainen,†** 1999 - HRT <sup>23</sup>	60	231	53	Finland	100	27 (10)	..	830	70	Vitamin D3 300 IU/day†† for 9 of 12 months per year vs placebo	Hormone treatment	..
Komulainen, †** 1999 - no HRT <sup>23</sup>	60	227	53	Finland	100	28 (11)	..	840	69	Vitamin D3: 300 IU/day†† for 9 of 12 months per year vs placebo	Calcium 93 mg/day	..
Hunter,† 2000 <sup>24</sup>	24	158	59 (47-70)	UK	100	71 (29)	104§	1055	63	Vitamin D3 800 IU/day vs placebo	..	..
Patel, 2001 <sup>25</sup> ‡‡	12	70	47 (23-70)	UK	100	72 (30-119)	+25§	570	68	Vitamin D3 800 IU/day vs placebo	..	..
Venkatachalam, 2003 <sup>26</sup>	24	50	54	UK	68	..	..	..	..	Intramuscular vitamin D 300 000 IU/year vs placebo	..	Treated coeliac disease
Cooper,† 2003 <sup>27</sup>	24	187	56	Australia	100	82 ± 26	81§	780	67	Vitamin D2: 10 000 IU/week vs placebo	Calcium 1 g/day	..
Harwood,†** 2004 <sup>28</sup>	12	75	80 (67-92)	UK	100	29 (10-67)	40§  §§	..	BMI 24 kg/m <sup>2</sup>	Intramuscular vitamin D2 300 000 IU vs no treatment	No placebo or calcium	..
Aloia,† 2005 <sup>29</sup>	36	208	61 (50-75)	USA (100% AA)	100	46 (19; 10-100)	87	760	79	Vitamin D3 800 IU/day for 2 years then 2000 IU/day vs placebo	Calcium, to 1.2-1.5 g/day total intake	..
Zhu,*† 2008 <sup>30</sup>	60	79	75 (inclusion criteria 70-80) ¶¶	Australia	100	68 (26)	106§	990	70	Vitamin D2 1000 IU/day vs placebo	Calcium 1.2 g/day	..
Zhu,† 2008 <sup>31</sup>	12	302	77	Australia	100	44 ± 13	60§	1100	73	Vitamin D2 1000 IU/day vs placebo	Calcium 1 g/day	..
Andersen, 2008 <sup>32</sup>	12	173	37¶	Pakistanis in Denmark	51	16¶ (IQR 11-22)	45§	530¶	73¶	Vitamin D3 400 IU/day vs 800 IU/day vs placebo	..	..
Viljakainen,† 2009 <sup>33</sup>	6	54	29 (21-49)	Finland	0	62 ± 15	82§	1340	79	Vitamin D3 400 IU/day vs 800 IU/day vs placebo	..	..

(Continues on next page)

Trial duration (months)	N	Mean age (range; years)	Country	Sex (% female)	Mean 25OHD (SD or range; nmol/L)		Dietary calcium (mg/day)	Weight (kg)	Intervention	Co-interventions*	Comorbidities	
					Baseline	On vitamin D						
(Continued from previous page)												
Islam, 2010 <sup>34</sup>	12	100	22	Bangladesh	100	36 (10-7)	68§	..	49	Vitamin D3 400 IU/day vs placebo	..	..
Jorde, 2010 <sup>35</sup>	12	421	47 (21-70)	Norway	63	58 ± 21	141§	..	BMI 35 kg/m <sup>2</sup>	Vitamin D3 40 000 IU/week vs 20 000 IU/week vs placebo	Calcium 500 mg/day	Overweight
Verschueren, 2011 <sup>36</sup>	6	113	80 (inclusion criteria >70)¶¶¶	Belgium	100	53 (34)	146§	..	67	Vitamin D3 880 IU/day vs 1600 IU/day	Vibration, factorial design	..
Grimnes,† 2012 <sup>37</sup>	12	297	63 (inclusion criteria 50-80)¶¶¶	Norway	100	71 (23)	185§	820	BMI 25 kg/m <sup>2</sup>	Vitamin D3 800 IU/day vs 6500 IU/day	Calcium 1 g/day	..
Rastelli, 2011 <sup>38</sup>	6	60	62	USA (13% AA)	100	56 ± 12	74§	..	BMI 32 kg/m <sup>2</sup>	Vitamin D2 50 000 IU/week vs per month vs placebo	Calcium 1 g/day, vitamin D3 400 IU/day	Anastrozole
Steffensen,† 2011 <sup>39</sup>	22	71	40 (21-50)	Norway	71	56 (25; 18-143)	123§	..	BMI 26 kg/m <sup>2</sup>	Vitamin D3 20 000/week vs placebo	Calcium 0.5 g/day	Multiple sclerosis
Nieves,† 2012 <sup>40</sup>	24	127	62	USA (100% AA)	100	29 (13)	55§	1000	82	Vitamin D3 1000 IU/day vs placebo	Calcium to 1 g/day total intake	..

Age and 25OHD were assessed at baseline, unless shown otherwise. Komulainen and colleagues<sup>33</sup> study included two cohorts, only one of which received hormone treatment, so these studies are presented separately; therefore, 24 cohorts are shown in the table. N=Number of participants randomly assigned. HRT=hormone replacement therapy. AA=African-American. 25OHD=25-hydroxyvitamin D. \*Given to both groups. †Compliance reported. ‡Measured during study in group on low dose of vitamin D or placebo. §25OHD concentrations were significantly higher during the study than in the control group. ¶Median IQR. Other values for age, 25OHD, calcium intake, and weight are mean. ||25OHD concentrations significantly increased during the study in the vitamin D group. \*\*Unblinded study. ††100 IU/day in year 5. ‡‡12 month intervention in a crossover study, crossover study starting in late summer. This is the treatment effect derived with multivariate regression analysis. §§1 year after injection of vitamin D. ¶¶¶Entry criteria for study; other values are actual age ranges. ||||Including supplements.

**Table 1: Characteristics of randomised controlled trials assessing the effects of vitamin D on bone mineral density in adults**

studies had to be randomised controlled trials comparing interventions that differed only in vitamin D content, which were done in adults (average age >20 years). The intervention could be a preparation of vitamin D3 or D2, but not a vitamin D metabolite. If other interventions were given (eg, calcium), they had to be the same in all groups. Studies of individuals with other disorders likely to affect bone and calcium metabolism (eg, chronic kidney disease, pregnancy, glucocorticoid use, and anti-epileptic drug use) were not eligible. Data for bone mineral density (or in the case of forearm assessment, bone mineral content) had to be available, irrespective of whether this was the primary endpoint. There were no language restrictions on trial eligibility.


We searched Web of Science, Embase, and the Cochrane Database from inception to July 8, 2012, with the terms “vitamin D”, or “c(h)olecalciferol”, or “ergocalciferol”, together with either “randomised study”, “randomised trial”, or “controlled clinical trial”. Additionally, the reference lists of reviews of vitamin D were screened for qualifying studies.<sup>5,11-16</sup> Two authors (IRR, MJB) independently confirmed the eligibility of studies

and collated the data from the qualifying studies. IRR extracted the data which were double checked by MJB and discrepancies resolved through discussion. Study quality was assessed as recommended in the Cochrane Handbook.<sup>17</sup> The complete search strategy is available in the appendix.

**Statistical analysis**

The primary endpoint was the percentage change in bone mineral density from baseline. We pooled data with a random effects meta-analysis with weighted mean differences and 95% CIs reported. To assess heterogeneity in results of individual studies, we used Cochran’s Q statistic and the I<sup>2</sup> statistic (I<sup>2</sup>>50% was used as a threshold indicating significant heterogeneity). Publication bias was assessed with Funnel plots and Egger’s regression model. The effects of vitamin D on bone mineral density were compared between subgroups of trials defined by pre-specified characteristics (eg, baseline age, vitamin D status, treatment dose, and trial duration). All tests were two-tailed and a p value of less than 0.05 was deemed statistically significant. We analysed data with Comprehensive Meta-Analysis (version 2).

See Online for appendix



**Figure 1: Meta-analysis of the effects of vitamin D supplementation on BMD at five skeletal sites**  
 Weighted mean difference in (A) lumbar spine BMD, (B) femoral neck BMD, (C) total hip or trochanter BMD, (D) total body BMD, or (E) forearm BMD. BMD=bone mineral density. HRT=hormone replacement therapy. \*HRT. †No HRT.

### Role of the funding source

The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. IRR and MJB had full access to all the data in the study and had final responsibility for the decision to submit for publication.

### Results


Our search strategy identified 3930 unique publications, the titles and abstracts of which were screened for inclusion. The full text of 54 articles was retrieved, of which 23 met the inclusion criteria (appendix). Reasons for exclusion of the remaining articles were: intervention not vitamin D (12), patients too young (two), study not randomised (two), duplicate publication (five), no data for bone mineral density presented (six), and patients had other major pathologies (four).

Table 1 shows descriptive data for the 23 qualifying trials, and figure 1 shows the data for bone mineral density data. One study (Komulainen and colleagues) included two cohorts, one receiving and one not receiving hormone

treatment, which are presented separately, so 24 cohorts are shown in the table. 18 studies were placebo-controlled, two had open control groups<sup>22,28</sup> (but in one of these, investigators assessing bone density assessment were masked to treatment group<sup>22</sup>), and three were comparisons between two different doses of vitamin D.<sup>20,37,38</sup> 19 studies were double-blind, and in one (presented in abstract only)<sup>26</sup> blinding was not described. A rigorous method of randomisation was explicitly described in 14 studies, and allocation concealment in ten studies; in the remainder, this information was absent or unclear. One study did not provide details of participants who withdrew or were lost to follow-up.<sup>22</sup> Participant completion rates ranged from 61% to 96%, and the weighted mean was 84%. Two studies<sup>30,38</sup> seemed to have more non-completers in the vitamin D group than in the control group, and one study<sup>40</sup> had more non-completers in the control group. Compliance was more than 80% in the 14 studies in which it was reported. Findings from two recent studies showed bone mineral density at only one site,<sup>30</sup> and Egger's test showed evidence of bias towards positive results at both hip sites (figure 2), but not elsewhere (data not shown), suggesting selective reporting.

The studies recruited 4082 participants, 92% women. In six studies (n=871) the average age was younger than 50 years, and the weighted mean age for the 24 cohorts was 59 years. 19 studies included mainly white populations, two were done exclusively in African-American individuals,<sup>29,40</sup> one took place in Bangladesh,<sup>34</sup> and another studied Pakistani immigrants in Denmark.<sup>32</sup> Two studies included mainly overweight populations.<sup>35,38</sup> 25-hydroxyvitamin D concentration was measured at baseline in all individuals in 19 studies, in 15% in one study,<sup>23</sup> and omitted in three.<sup>18,22,26</sup> A wide range of baseline concentrations of 25-hydroxyvitamin D were reported. The mean level was less than 30 nmol/L in five studies (n=1181), 30–50 nmol/L in three studies (n=610), 50–75 nmol/L in 11 studies (n=1860), and more than 75 nmol/L in only one study (187 healthy Australian women in early postmenopause). In 12 studies, calcium supplements were given to all trial groups. Two studies (n=243) had average total calcium intakes of less than 750 mg per day.<sup>25,32</sup> One study<sup>25</sup> used a crossover design whereas the others were all parallel group studies. Three small studies were of 6 months duration, eight for 1 year, and 12 for 2–5 years. The weighted mean trial duration was 23·5 months.

Various supplement regimens were assessed. Most trials used daily oral dosing, although in two studies, supplementation was given only for 9 months of each year. Four studies (n=739) dosed participants at weekly or monthly intervals, and two studies (n=125) gave annual intramuscular injections of 300 000 units. When doses are averaged, 500 IU per day or less was given in six studies (n=1648), 500–799 IU per day in four studies (n=646), and 800 IU per day or more in 13 studies (n=1788). Three studies had three groups (two different



**Figure 2:** Funnel plots of femoral neck (A) and total hip (B) bone mineral density data, testing for publication bias

Evidence of positive bias (assessed with Egger's test) was apparent for both, but not at the other bone mineral density measurement sites (data not shown).

vitamin D doses and a control group).<sup>32,33,35</sup> In one of these studies,<sup>32</sup> the results were reported separately for men and women. For this study, we pooled the results for men and women, and for all three studies, the results from the two vitamin D groups were pooled and compared with the control group.

Follow-up concentrations of 25-hydroxyvitamin D were reported in 19 studies; in all cases, concentrations were significantly increased in individuals on treatment (table 1). The unweighted mean across all studies increased from 53 nmol/L to 92 nmol/L.

Bone mineral density was measured at one to five sites (lumbar spine, femoral neck, total hip, trochanter, total body, or forearm) in each study (figure 1). The total hip site was assessed in 12 studies and the trochanter in three.<sup>21,27,34</sup> Because the trochanter is the major component of the total hip, we have analysed these data together. There were six findings of statistically significant beneficial effects on bone mineral density, four studies reported beneficial effects at one site only,<sup>19-21</sup> and one study<sup>34</sup> reported beneficial effects in both femoral regions (figure 1). Each of these studies assessed other sites and failed to find significant effects. Two studies reported detrimental effects at the total body ( $p \leq 0.05$ ).<sup>32,43</sup>

In three of the five studies with positive outcomes, baseline 25-hydroxyvitamin D concentrations were low (26, 29, and 36 nmol/L),<sup>21,28,34</sup> but in the other two, concentrations of 25-hydroxyvitamin D in the control group were 66 and 71 nmol/L.<sup>19,20</sup> Four studies<sup>23,29,31,32</sup> with baseline 25-hydroxyvitamin D concentrations of less than 50 nmol/L did not produce positive outcomes, although in one study, the vitamin D dose was only 195 IU per day and in another, 1 g calcium was given to both groups every day.<sup>31</sup> Three of the positive studies used vitamin D doses of 400 IU per day,<sup>19,21,34</sup> one compared 700 IU per day with 100 IU per day,<sup>20</sup> and one provided 300 000 IU per year (820 IU per day) by injection.<sup>28</sup> Three positive studies were of 12 months duration, and two lasted 24 months.

All positive studies were in women, four in older white women<sup>19-21,28</sup> and one in Bangladeshi women.<sup>34</sup> Thus, no suggestion of ethnic differences in response was evident. Studies comparing higher vitamin D doses with 800 IU per day<sup>36,37</sup> showed no differences.

Figure 1 shows the results of the meta-analysis. Two studies from table 1 were not included in this analysis. In the Venkatachalam study<sup>26</sup> there was a 9-year age difference between the two treatment groups (49 years vs 58 years), suggesting that differences in bone loss might not only be related to treatment allocation. The bone mineral density changes tended to be more positive in the placebo group in this study, but this finding was not significant (data not shown). The Viljakainen study<sup>33</sup> was excluded because no quantitative data in the original publication were available, and we have been unable to obtain them from the authors. Investigators of the original publication reported no effects on bone mineral density.

We reported no significant effect of vitamin D on bone mineral density in either the spine or total hip. By contrast, we noted a significant increase in femoral neck bone mineral density, but evidence of heterogeneity in the data (figure 1). Meta-regression exploring the effects of age, study duration, number of participants, sex, 25-hydroxyvitamin D concentration, weight, vitamin D dose, baseline bone mineral density, and type of DXA machine on the femoral neck bone mineral density treatment effect did not show any significant interactions (data not shown). In the forearm and total body scans, both predominantly assessing cortical bone, net changes were negative, although neither was significant (figure 1). We recorded evidence of bias towards positive results at both hip sites, which might have contributed to the positive femoral neck results. However, an analysis restricted to the studies that reported both spine and femoral neck showed the change in bone mineral density to be greater at the femoral neck ( $p=0.012$ ; data not shown). A similar comparison in studies reporting both

	25OHD concentrations			Dose			Duration			Calcium										
	<50 nmol/L		≥50 nmol/L	<800		≥800	≤12 months		>12 months	Calcium		No calcium	p value							
	n	% difference	n	% difference	n	% difference	n	% difference	n	% difference	n	% difference	n	% difference						
Lumbar spine	7	0.1 (-0.3 to 0.5)	9	0.0 (-0.3 to 0.3)	0.9	7	0.4 (0.0 to 0.8)*	10	-0.1 (-0.4 to 0.2)	0.04	8	0.1 (-0.4 to 0.6)	9	0.0 (-0.4 to 0.3)	0.6	10	0.1 (-0.2 to 0.3)	7	0.1 (-0.6 to 0.7)	>0.9
Total hip	6	0.6 (-0.1 to 1.2)	9	0.0 (-0.2 to 0.2)	0.09	2	1.4 (-1.8 to 4.5)	13	0.1 (-0.1 to 0.3)	0.4	8	0.2 (-0.2 to 0.7)	7	0.2 (-0.1 to 0.5)	0.8	9	0.0 (-0.2 to 0.2)	6	0.7 (-0.1 to 1.6)	0.1
Femoral neck	6	1.0 (0.2 to 1.9)*	6	0.5 (-0.2 to 1.3)	0.2	6	1.4 (0.4 to 2.4)*	7	0.3 (-0.2 to 0.8)	0.06	5	1.2 (-0.1 to 2.4)	8	0.7 (0.0 to 1.3)*	0.5	5	0.4 (-0.5 to 1.3)	8	1.1 (0.4 to 1.9)*	0.2
Forearm	2	-0.3 (-0.7 to 0.2)	3	-0.4 (-1.2 to 0.4)	0.6	1	-0.3 (-4.9 to 4.3)	5	-0.3 (-0.7 to 0.1)	>0.9	..	..	6	-0.3 (-0.7 to 0.1)	..	4	-0.3 (-0.7 to 0.1)	2	-0.7 (-1.7 to 0.4)	0.5
Total body	3	-0.7 (-1.9 to 0.5)	5	0.0 (-0.2 to 0.2)	0.3	3	-0.6 (-1.7 to 0.6)	5	-0.1 (-0.3 to 0.1)	0.4	5	-0.5 (-1.1 to 0.2)	3	0.1 (-0.2 to 0.3)	0.12	5	0.0 (-0.1 to 0.2)	3	-0.9 (-2.1 to 0.4)	0.2

For n, several studies in subgroup. p value for heterogeneity between subgroups. 25OHD=25-hydroxyvitamin D. \*Changes for which the CIs do not cross zero.

Table 2: Meta-analysis of vitamin D effects on bone mineral density in subgroups of trials



femoral neck and total hip or trochanter did not find those sites to be different ( $p=0.31$ ; data not shown).

Table 2 summarises effects of bone mineral density in subgroups of trials categorised according to study characteristics. These data suggest that benefits are more pronounced in studies using vitamin D doses of less than 800 IU per day in the lumbar spine, and this effect was independent of the effects of baseline 25-hydroxyvitamin D (data not shown). Study duration and administration of calcium to all trial participants did not affect outcomes. The effect of mean age was analysed similarly in three categories: individuals younger than 50 years, 50–75 years, and 75 years or older. We noted no evidence of an age effect ( $p$  values 0.15–0.6 for the various sites; data not shown). Three trials had an open-label study design,<sup>22,23,28</sup> and two studies<sup>30,36</sup> reported results for only one bone mineral density site, raising the possibility of selective reporting. We did a sensitivity analysis excluding these five trials at higher risk of bias. Analyses of the remaining 16 trials produced very similar results for each bone mineral density site to the overall results (data not shown), suggesting that trial quality did not affect outcomes.

## Discussion

This systematic review provides very little evidence of an overall benefit of vitamin D supplementation on bone density. Although small increases in bone density at some skeletal sites in some studies were reported, when these increases are offset against the individual findings of deleterious effects, the number of positive results is little better than what would have been expected by chance. Findings of the meta-analysis are similar; we reported a small but significant increase in bone density in the femoral neck, but not at the closely related total hip site. Such a localised effect could be artifactual, or could be a chance finding. The femoral neck has more cortical bone than does the total hip region and is usually less responsive to interventions than are trabecular-rich sites, including to the treatment of osteomalacia.<sup>44</sup> The other cortical-rich sites (forearm and total body) did not show a positive effect, so this is not a cortical-specific effect. Single-site effects on bone mineral density have not been associated with reduction in fractures in individuals given other interventions.

Several studies merit individual mention. Results from the investigation by Tuppurainen and colleagues<sup>22</sup> showed the largest end-of-study increases in femoral neck bone mineral density. This large difference between groups at 5 years is contrary to what was reported at 1 and 2 years, when the vitamin D group had smaller increases in bone mineral density than did the control group. No significant benefit was noted from the use of vitamin D during the whole study. However, exclusion of the Tuppurainen study<sup>22</sup> from the meta-analysis of bone mineral density of femoral neck does not change the results. The only studies to show significant increases in

bone mineral density in populations not deficient in vitamin D were from the two studies by Dawson-Hughes and coworkers.<sup>19,20</sup> The reasons for these atypical responses are not clear, but both studies were undertaken at different times in the same cohort, so they are not independent studies. This cohort was originally selected for its low dietary calcium intake (<400 mg per day). These are very low calcium intakes for a western population, suggesting that these data should not be generalised to most western women who need prophylaxis against postmenopausal osteoporosis. Islam and colleagues' study<sup>34</sup> is notable because of the finding of clinically significant increases in bone density at the total hip and femoral neck. These might be chance findings, but this study was done in Bangladeshi women with mean baseline 25-hydroxyvitamin D concentrations of 36 nmol/L, who are likely to have had low dietary calcium intakes, although these data were not reported. Why findings from other studies in populations with similarly low 25-hydroxyvitamin D concentrations did not show improvements in bone density is unclear, but might be accounted for by increased calcium intakes or by the well recognised inaccuracy of many assays for 25-hydroxyvitamin D<sup>45</sup>—ie, the participants in Islam and coworkers' study<sup>34</sup> might have been more deficient in vitamin D than the measurements suggest. The more recent studies in this review (ie, done in the past 5 years) used mass spectrometry or the more reliable of the immunoassays,<sup>43</sup> so should have identified seriously deficient populations.

The negative findings from this systematic review of the effects of vitamin D supplementation on bone density are entirely consistent with those from meta-analyses of the efficacy of this intervention at reducing the risk of fracture.<sup>7,8</sup> These findings sharply conflict with those of other reviews, which show that vitamin D has a substantial beneficial effect on fracture risk.<sup>46,47</sup> These reviews invariably include studies in which calcium and vitamin D is the intervention assessed. Calcium supplements suppress bone turnover by about 20% and have beneficial effects on bone density,<sup>48</sup> so inclusion of studies in which calcium is part of the intervention and attributing the benefits to vitamin D is inappropriate. The effects of the combination of calcium and vitamin D on fracture risk are indistinguishable from those of calcium alone,<sup>49</sup> suggesting that vitamin D contribution is small in most studies. Findings from the study by Chapuy and coworkers<sup>50</sup> have most clearly shown the benefits of calcium and vitamin D. In this study, the placebo group had very low 25-hydroxyvitamin D concentrations (mean 25 nmol/L, measured in 69 women in the placebo group at 12 months) and calcium intakes of only 500 mg per day. Intervention produced a difference between groups in total hip bone mineral density of 7.3%, so the 27% reduction in hip fractures was not surprising. These benefits are consistent with the effects of vitamin D and calcium on bone mineral density in

individuals who are markedly vitamin D deficient (some possibly osteomalacic). The suggested benefit of vitamin D plus calcium on falls<sup>51</sup> might have contributed to the positive outcome in the study by Chapuy and colleagues. The changes in bone mineral density recorded in our meta-analysis are much smaller than those associated with fracture prevention from any intervention. Thus, the antifracture efficacy noted in the Chapuy study should not be expected to be reproduced in substantially less deficient populations, or from the use of vitamin D alone.

The negative findings of our analysis contrast with the widely held perception that vitamin D works directly on bone cells to promote mineralisation.<sup>31,35,52</sup> This perception is probably incorrect. Although the vitamin D receptor knockout mouse has reduced bone mass, this phenotype can be completely corrected and normal mineralisation restored by the provision of calcium and phosphate supplements.<sup>42</sup> Findings of studies of selective vitamin D receptor knockout show that the skeletal phenotype of the vitamin D receptor knockout mouse can be reproduced by selective knockout of the receptor in enterocytes,<sup>53</sup> and that the skeletal abnormalities of the receptor global knockout mouse can be corrected by selective replacement of the vitamin D receptor in enterocytes.<sup>54,55</sup> Thus, expression of the vitamin D receptor in enterocytes is both necessary and adequate for normal bone mineralisation. Selective loss of vitamin D receptor from bone actually increases bone mass.<sup>53,56</sup> This finding can be explained by the fact that vitamin D receptor in bone (in cells of the osteoblast lineage) regulates RANKL and osteoprotegerin production to stimulate osteoclastogenesis.<sup>57</sup> Additionally, vitamin D directly inhibits mineralisation of bone, through increasing local pyrophosphate concentrations.<sup>53</sup> Thus, vitamin D is not a compound mainly responsible for maintenance of bone calcium content, but rather for maintenance of circulating calcium concentrations, which are crucial for cardiac and neuronal function. Bone is merely a reservoir that can be drawn on for this purpose. Of course, in states of vitamin D deficiency, secondary hyperparathyroidism arises, which also stimulates the production of RANKL and osteoclastogenesis. Thus, the biphasic effects of vitamin D on bone mass are unsurprising, because either low or high concentrations can potentially accelerate bone resorption. Some studies of high-dose calciferol or 1 $\alpha$ -hydroxylated vitamin D metabolites show increased bone loss<sup>58</sup> and fractures,<sup>59,60</sup> which is consistent with this finding of biphasic effects.

Although our analysis has restrictions common to individual studies (some were unblinded, were short term, used low doses of vitamin D, and most participants had adequate calcium intakes), it also has many strengths. The total number of participants is large for assessment of a bone mineral density endpoint, most individual studies were well powered, with wide ranges of baseline 25-hydroxyvitamin D concentrations, vitamin D

doses, dosing regimens, and ethnic groups. Therefore, the failure of any one study and of the meta-analysed data to show consistent benefit across the skeleton is likely to be a real finding.

The clinical implication of our findings is that the widespread use of vitamin D supplements for skeletal protection in adults without specific risk factors for vitamin D deficiency is not justified. This assertion complies with findings from previous meta-analyses of studies of fracture,<sup>7,8</sup> and suggests that no basis exists for the notion that those studies failed to detect a clinically significant benefit as a result of deficiencies in design or execution. The small effects of vitamin D supplements on bone mineral density do not exclude a beneficial effect on fracture by prevention of falls,<sup>51</sup> although findings from the meta-analyses of fracture provide no evidence of this effect.<sup>7,8</sup> Individuals at risk of vitamin D deficiency as a result of skin pigmentation or low sunlight exposure (eg, a result of veiling or frailty) might indeed benefit, so targeting of the intervention is important if the balance of risk and benefit is to be positive.

Further studies of vitamin D supplements in these groups are needed to establish associations between baseline 25-hydroxyvitamin D concentration and responses to vitamin D supplements. Such analyses might contribute to an improved definition of vitamin D deficiency. In the past few years, some clinicians have been enthusiastic about use of vitamin D supplements in doses of more than 1000 IU per day, with a view to achieve serum 25-hydroxyvitamin D concentrations greater than 75 nmol/L. Our analysis gives no support for this target concentration of 25-hydroxyvitamin D, because the existing evidence of benefit on bone mineral density comes from doses of 400–800 IU per day. In fact, data from studies<sup>36,37</sup> comparing high-dose with low-dose vitamin D supplements suggest that individuals on a low dose have improved bone mineral density, although differences between the groups were not significant. Although these conclusions contrast with those of many advocates in the specialty, they align well with the 2010 report from the Institute of Medicine,<sup>5</sup> which concluded (partly on the basis of histological evidence) that 40 nmol/L was an adequate concentration of serum 25-hydroxyvitamin D, and that most adults in North America do not need supplementation. The increasing practice for measurement and supplementation of vitamin D is expensive.<sup>61</sup> Our data suggest that the targeting of low-dose vitamin D supplements only to individuals who are likely to be deficient could free up substantial resources that could be better used elsewhere in health care.

#### Contributors

All authors developed the concept of this study. IRR and MJB wrote the protocol. IRR and MJB collated the data for the study and MJB did the statistical analyses. The first draft of the manuscript was written by IRR and thoroughly revised by MJB and AG.

#### Conflicts of interest

We declare that we have no conflicts of interest.



## Acknowledgments

This study was funded by the Health Research Council of New Zealand. We thank Greg Gamble for assistance with the meta-regression analyses.

## References

- Arabi A, Baddoura R, El-Rassi R, Fuleihan GEH. PTH level but not 25 (OH) vitamin D level predicts bone loss rates in the elderly. *Osteoporos Int* 2012; **23**: 971–80.
- Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. *Osteoporos Int* 1997; **7**: 439–43.
- Marwaha RK, Tandon N, Garg MK, et al. Bone health in healthy Indian population aged 50 years and above. *Osteoporos Int* 2011; **22**: 2829–36.
- Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B, et al. Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among US adults. *J Bone Miner Res* 2009; **24**: 935–42.
- Committee to review dietary reference intakes for vitamin D and calcium. Dietary reference intakes for calcium and vitamin D. Washington DC: The National Academies Press, 2010.
- Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. *Osteoporos Int* 2005; **16**: 713–16.
- Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev* 2009; **2**: CD000227.
- Abrahamsen B, Masud T, Avenell A, et al. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. *BMJ* 2010; **340**: B5463.
- Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium/vitamin D supplements and cardiovascular events: a re-analysis of the Women's Health Initiative limited-access dataset, and meta-analysis of calcium with or without vitamin D. *BMJ* 2011; **342**: 2040.
- Bailey RL, Dodd KW, Goldman JA, et al. Estimation of total usual calcium and vitamin D intakes in the United States. *J Nutr* 2010; **140**: 817–22.
- Cranney A, Horsley T, O'Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. *Evid Rep Technol Assess (Full Rep)* 2007; **158**: 1–235.
- Chung M, Balk EM, Brendel M, et al. Vitamin D and calcium: a systematic review of health outcomes. *Evid Rep Technol Assess (Full Rep)* 2009; **183**: 1–420.
- Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. *Best Pract Res Clin Endocrinol Metab* 2011; **25**: 585–91.
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2011; **96**: 1911–30.
- Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the US Preventive Services Task Force. *Ann Intern Med* 2011; **155**: 827–38.
- Papadimitropoulos E, Wells G, Shea B, et al. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. *Endocrine Rev* 2002; **23**: 560–69.
- Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane handbook for systematic reviews of interventions* version 501. Chichester, UK: Wiley, 2008.
- Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund KE, Transbol IB. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. *Eur J Clin Invest* 1980; **10**: 273–79.
- Dawson-Hughes B, Dallal GE, Krall EA, Harris S, Sokoll LJ, Falconer G. Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. *Ann Intern Med* 1991; **115**: 505–12.
- Dawson-Hughes B, Harris SS, Krall EA, Dallal GE, Falconer G, Green CL. Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. *Am J Clin Nutr* 1995; **61**: 1140–45.
- Ooms ME, Roos JC, Bezemer PD, Vandervijgh WJF, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. *J Clin Endocrinol Metab* 1995; **80**: 1052–58.
- Tuppurainen MT, Komulainen M, Kroger H, et al. Does vitamin D strengthen the increase in femoral neck bmd in osteoporotic women treated with estrogen. *Osteoporos Int* 1998; **8**: 32–38.
- Komulainen M, Kroger H, Tuppurainen MT, et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D, in early postmenopausal women: a population-based 5-year randomized trial. *J Clin Endocrinol Metab* 1999; **84**: 546–52.
- Hunter D, Major P, Arden N, et al. A randomized controlled trial of vitamin D supplementation on preventing postmenopausal bone loss and modifying bone metabolism using identical twin pairs. *J Bone Miner Res* 2000; **15**: 2276–83.
- Patel R, Collins D, Bullock S, Swaminathan R, Blake GM, Fogelman I. The effect of season and vitamin D supplementation on bone mineral density in healthy women: a double-masked crossover study. *Osteoporos Int* 2001; **12**: 319–25.
- Venkatachalam S, Gupta R, Speden D, et al. A randomised controlled trial of parenteral vitamin D in coeliac disease—bone density changes. *Osteoporos Int* 2003; **14** (suppl 4): 39–40.
- Cooper L, Clifton-Bligh PB, Nery ML, et al. Vitamin D supplementation and bone mineral density in early postmenopausal women. *Am J Clin Nutr* 2003; **77**: 1324–29.
- Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. *Age Ageing* 2004; **33**: 45–51.
- Aloia JF, Talwar SA, Pollack S, Yeh J. A randomized controlled trial of vitamin D-3 supplementation in African American women. *Arch Intern Med* 2005; **165**: 1618–23.
- Zhu K, Devine A, Dick IM, Wilson SG, Prince RL. Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. *J Clin Endocrinol Metab* 2008; **93**: 743–49.
- Zhu K, Bruce D, Austin N, Devine A, Ebeling PR, Prince RL. Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. *J Bone Miner Res* 2008; **23**: 1343–48.
- Andersen R, Molgaard C, Skovgaard LT, et al. Effect of vitamin D supplementation on bone and vitamin D status among Pakistani immigrants in Denmark: a randomised double-blinded placebo-controlled intervention study. *Br J Nutr* 2008; **100**: 197–207.
- Viljakainen HT, Vaisanen M, Kemi V, et al. Wintertime vitamin D supplementation inhibits seasonal variation of calcitropic hormones and maintains bone turnover in healthy men. *J Bone Miner Res* 2009; **24**: 346–52.
- Islam MZ, Shamim A, Viljakainen HT, et al. Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention. *Br J Nutr* 2010; **104**: 241–47.
- Jorde R, Sneve M, Torjesen PA, Figenschau Y, Hansen JB, Grimnes G. No significant effect on bone mineral density by high doses of vitamin D-3 given to overweight subjects for one year. *Nutrj* 2010; **9**: 1.
- Verschueren SMP, Bogaerts A, Delecluse C, et al. The effects of whole-body vibration training and vitamin D supplementation on muscle strength, muscle mass, and bone density in institutionalized elderly women: a 6-month randomized, controlled trial. *J Bone Miner Res* 2011; **26**: 42–49.
- Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almas B, Jorde R. The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass—a randomized controlled 1-year trial. *Osteoporos Int* 2012; **23**: 201–11.
- Rastelli AL, Taylor ME, Gao F, et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. *Breast Cancer Res Treat* 2011; **129**: 107–16.

- 39 Steffensen LH, Jorgensen L, Straume B, Mellgren SI, Kampman MT. Can vitamin D(3) supplementation prevent bone loss in persons with MS? A placebo-controlled trial. *J Neurol* 2011; **258**: 1624–31.
- 40 Nieves J, Cosman F, Grubert E, Ambrose B, Ralston S, Lindsay R. Skeletal effects of vitamin D supplementation in postmenopausal black women. *Calcif Tissue Int* 2012; **91**: 316–24.
- 41 Komulainen M, Kroger H, Tuppurainen MT, et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D, in early postmenopausal women: a population-based 5-year randomized trial. *J Clin Endocrinol Metab* 1999; **84**: 546–52.
- 42 Masuyama R, Nakaya Y, Katsumata S, et al. Dietary calcium and phosphorus ratio regulates bone mineralization and turnover in vitamin D receptor knockout mice by affecting intestinal calcium and phosphorus absorption. *J Bone Miner Res* 2003; **18**: 1217–26.
- 43 Binkley N, Krueger DC, Morgan S, et al. Current status of clinical 25-hydroxyvitamin D measurement: An assessment of between-laboratory agreement. *Clin Chim Acta* 2010; **411**: 1976–82.
- 44 El-Desouki MI, Othman SM, Fouda MA. Bone mineral density and bone scintigraphy in adult Saudi female patients with osteomalacia. *Saudi Med J* 2004; **25**: 355–58.
- 45 Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: A call for standardization. *J Clin Endocrinol Metab* 2004; **89**: 3152–57.
- 46 Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA* 2005; **293**: 2257–64.
- 47 Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med* 2012; **367**: 40–49.
- 48 Reid IR, Mason B, Horne A, et al. Randomized controlled trial of calcium in healthy older women. *Am J Med* 2006; **119**: 777–85.
- 49 Tang BMP, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. *Lancet* 2007; **370**: 657–66.
- 50 Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin-D3 and calcium to prevent hip fractures in elderly women. *N Engl J Med* 1992; **327**: 1637–42.
- 51 Murad MH, Elamin KB, Abu Elnour NO, et al. The effect of vitamin D on falls: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2011; **96**: 2997–3006.
- 52 Francis R, Aspray T, Fraser W, et al. Vitamin D and bone health: a practical clinical guideline for patient management. April, 2013. <http://www.nos.org.uk/document.doc?id=1352> (accessed May 20, 2013).
- 53 Lieben L, Masuyama R, Torrekens S, et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. *J Clin Invest* 2012; **122**: 1803–15.
- 54 Marks HD, Fleet JC, Peleg S. Transgenic expression of the human vitamin D receptor (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption. *J Steroid Biochem Mol Biol* 2007; **103**: 513–16.
- 55 Xue Y, Fleet JC. Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. *Gastroenterology* 2009; **136**: 1317–1327.
- 56 Tanaka H, Seino Y. Direct action of 1,25-dihydroxyvitamin D on bone: VDRKO bone shows excessive bone formation in normal mineral condition. *J Steroid Biochem Mol Biol* 2004; **89–90**: 343–45.
- 57 Haussler MR, Haussler CA, Whitfield GK, et al. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the “fountain of youth” to mediate healthful aging. *J Steroid Biochem Mol Biol* 2010; **121**: 88–97.
- 58 Ott SM, Chesnut CH. Calcitriol treatment is not effective in postmenopausal osteoporosis. *Ann Intern Med* 1989; **110**: 267–74.
- 59 Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA* 2010; **303**: 1815–22.
- 60 Ebeling PR, Wark JD, Yeung S, et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. *J Clin Endocrinol Metab* 2001; **86**: 4098–103.
- 61 Maxmen A. The vitamin D-lemma. *Nature* 2011; **475**: 23–25.